|Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer|
MCU Cheang, SK Chia, D Voduc, D Gao, S Leung, J Snider, M Watson, ...
JNCI: Journal of the National Cancer Institute 101 (10), 736-750, 2009
|The clonal and mutational evolution spectrum of primary triple-negative breast cancers|
SP Shah, A Roth, R Goya, A Oloumi, G Ha, Y Zhao, G Turashvili, J Ding, ...
Nature 486 (7403), 395-399, 2012
|Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype|
MCU Cheang, D Voduc, C Bajdik, S Leung, S McKinney, SK Chia, ...
Clinical cancer research 14 (5), 1368-1376, 2008
|Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early …|
A Schneeweiss, S Chia, T Hickish, V Harvey, A Eniu, R Hegg, C Tausch, ...
Annals of oncology 24 (9), 2278-2284, 2013
|Population-based validation of the prognostic model ADJUVANT! for early breast cancer|
IA Olivotto, CD Bajdik, PM Ravdin, CH Speers, AJ Coldman, BD Norris, ...
Journal of Clinical Oncology 23 (12), 2716-2725, 2005
|Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with …|
S Chia, W Gradishar, L Mauriac, J Bines, F Amant, M Federico, L Fein, ...
Journal of clinical oncology 26 (10), 1664-1670, 2008
|Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors|
Y Lou, PC McDonald, A Oloumi, S Chia, C Ostlund, A Ahmadi, A Kyle, ...
Cancer research 71 (9), 3364-3376, 2011
|Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution|
P Eirew, A Steif, J Khattra, G Ha, D Yap, H Farahani, K Gelmon, S Chia, ...
Nature 518 (7539), 422-426, 2015
|The impact of new chemotherapeutic and hormone agents on survival in a population‐based cohort of women with metastatic breast cancer|
SK Chia, CH Speers, Y D'yachkova, A Kang, S Malfair‐Taylor, J Barnett, ...
Cancer 110 (5), 973-979, 2007
|EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer|
L Hughes-Davies, D Huntsman, M Ruas, F Fuks, J Bye, SF Chin, J Milner, ...
Cell 115 (5), 523-535, 2003
|Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma|
SK Chia, CC Wykoff, PH Watson, C Han, RD Leek, J Pastorek, KC Gatter, ...
Journal of Clinical Oncology 19 (16), 3660-3668, 2001
|Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3|
DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ...
J Clin Oncol 36 (24), 2465-2472, 2018
|Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 …|
A Chan, S Delaloge, FA Holmes, B Moy, H Iwata, VJ Harvey, NJ Robert, ...
The Lancet Oncology 17 (3), 367-377, 2016
|Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers|
S Chia, B Norris, C Speers, M Cheang, B Gilks, AM Gown, D Huntsman, ...
Journal of clinical oncology 26 (35), 5697-5704, 2008
|Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial|
M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ...
The lancet oncology 18 (12), 1688-1700, 2017
|Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double …|
J Baselga, SA Im, H Iwata, J Cortés, M De Laurentiis, Z Jiang, CL Arteaga, ...
The Lancet Oncology 18 (7), 904-916, 2017
|Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND. 163.|
SL Ellard, M Clemons, KA Gelmon, B Norris, H Kennecke, S Chia, ...
Clin Oncol 27 (27), 4536-4541, 2009
|A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen|
SK Chia, VH Bramwell, D Tu, LE Shepherd, S Jiang, T Vickery, E Mardis, ...
Clinical cancer research 18 (16), 4465-4472, 2012
|Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast|
CC Wykoff, N Beasley, PH Watson, L Campo, SK Chia, R English, ...
The American journal of pathology 158 (3), 1011-1019, 2001
|Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy|
FP O’malley, S Chia, D Tu, LE Shepherd, MN Levine, VH Bramwell, ...
Journal of the National Cancer Institute 101 (9), 644-650, 2009